E
Eirion Therapeutics
A clinical stage biopharmaceutical company that is developing next-generation prescription products for aesthetic dermatology
About Eirion Therapeutics
Eirion Therapeutics, Inc. is a clinical-stage biopharmaceutical company established in 2016, with its headquarters in Woburn, Massachusetts. The company, founded by Jon Edelson, MD, who also serves as its Chairman, CEO, and President, is focused on developing prescription products for the aesthetic dermatology market. Dr. Edelson has over 25 years of experience founding and leading healthcare companies, several of which were acquired by major pharmaceutical and healthcare firms.
Eirion's business model centers on the research and development of a pipeline of drug candidates, with a strategy that involves outsourcing most manufacturing and clinical trial tasks to partners, allowing for a capital-efficient operation. A significant part of its revenue strategy includes licensing agreements. In March 2021, Eirion closed a major deal with Shanghai Haohai Biological Technology, a publicly traded Chinese company. This arrangement included a $32 million Series A investment and an $8 million upfront payment for exclusive rights to develop and commercialize all of Eirion's products in China. The deal holds the potential for approximately $43 million in development fees and up to $444 million in sales milestones, with royalties.
The company's product pipeline targets several key areas within aesthetic medicine: wrinkles, hair loss (androgenic alopecia), hair graying, and excessive sweating (primary axillary hyperhidrosis). The pipeline includes several candidates: * **ET-02**: A topical small molecule for treating androgenic alopecia and hair graying. It operates on a novel mechanism that aims to reactivate dormant hair follicle stem cells without affecting hormonal pathways. A first-in-human Phase 1 trial in January 2025 showed promising results, with a 5% solution leading to a six-fold increase in non-vellus hair count compared to placebo after five weeks. A larger Phase 2 trial is planned for 2025. * **ET-01**: A topical botulinum product for wrinkles. This product uses a proprietary two-step process involving microporation of the skin followed by the application of a nanoemulsion delivery system to avoid the need for injections. * **AI-09**: A ready-to-use liquid injectable botulinum formulation that does not require refrigeration or reconstitution and is albumin-free. A Phase 1-2 trial showed it was safe and effective for glabellar wrinkles, with a median duration of 26 weeks. * **ET-03**: An oral version of the same small molecule found in ET-02, also intended for hair loss and graying.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2021 | $40M | $160M | Shanghai Haohai Biological Technology | — |
| SEEDEquity / VC | Jan 2018 | $0 | — | Gore Range Capital | — |
Growth signals
Latest recorded traffic for Eirion Therapeutics is 2.5K monthly website visits, down 47.9% over the last three months. Eirion Therapeutics's team declined 10% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Eirion Therapeutics in the Woburn ecosystem
The Eirion Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Gore Range Capital
Series A1 investor entered at this stage
Shanghai Haohai Biological Technology
Other known investors1 additional known investor
Scientific Health Development Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Eirion Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eirion Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.